Vanguard Group
PHAS

Vanguard Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Vanguard Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,808,098
Closed -$318K – 4605
2022
Q3 		$318K Hold
1,808,098
– – ﹤0.01% 4333
2022
Q2 		$1.08M Sell
1,808,098
-18,033
-1% -$17.3K ﹤0.01% 4061
2022
Q1 		$2.41M Sell
1,826,131
-8,772
-0.5% -$14.2K ﹤0.01% 3888
2021
Q4 		$4.79M Sell
1,834,903
-39,670
-2% -$120K ﹤0.01% 3639
2021
Q3 		$5.83M Buy
1,874,573
+5,909
+0.3% +$19.7K ﹤0.01% 3560
2021
Q2 		$6.95M Buy
1,868,664
+297,078
+19% +$989K ﹤0.01% 3399
2021
Q1 		$5.44M Buy
1,571,586
+809,659
+106% +$3.29M ﹤0.01% 3484
2020
Q4 		$2.56M Buy
761,927
+33,249
+5% +$119K ﹤0.01% 3597
2020
Q3 		$2.56M Sell
728,678
-9,175
-1% -$37K ﹤0.01% 3414
2020
Q2 		$3.39M Sell
737,853
-825
-0.1% -$3.65K ﹤0.01% 3260
2020
Q1 		$2.44M Sell
738,678
-2,461
-0.3% -$11.3K ﹤0.01% 3246
2019
Q4 		$4.53M Sell
741,139
-2,494
-0.3% -$10.3K ﹤0.01% 3201
2019
Q3 		$3.1M Buy
743,633
+70,013
+10% +$558K ﹤0.01% 3294
2019
Q2 		$8.84M Buy
673,620
+489,626
+266% +$6M ﹤0.01% 2929
2019
Q1 		$1.75M Buy
183,994
+8,000
+5% +$31.7K ﹤0.01% 3496
2018
Q4 		$544K Buy
+175,994
New +$697K ﹤0.01% 3721

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group's PHAS Position: Q4 2022 in Review

Vanguard Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 1,808,098 shares — an estimated $318K sold.

Vanguard Group first reported a position in PHAS in Q4 2018 and held it in 16 quarters. The position peaked at $8.84M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Vanguard Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 1,808,098 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $318K.
  • Vanguard Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
  • Vanguard Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $8.84M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.